A Call to Action for Hospitals, Governments, and Distributors
In a world where healthcare costs are rising and hospital-acquired infections (HAIs) are spiralling out of control, Venaican offers a groundbreaking, cost-saving, and safer alternative to traditional cannulation methods. Designed by a doctor with over 40 years of critical care experience, this spring-loaded self-introducing cannula is engineered to reduce failed cannulation attempts, lower infection risks, and dramatically minimise medical waste.
💡 Why Venaican?
Traditional IV cannulation is responsible for:
- Up to 35% of cannula wastage is due to failed first attempts, especially in children and older people.
- 8–10% of all hospital-acquired infections, according to the CDC.
- Increased hospital stay, averaging 2–7 additional days, costing $5,000–USD 20,000 per patient in high-income countries.
- Rising claims of iatrogenic injuries that often go uncompensated by insurance providers.
Venaican directly addresses these failures by offering a dual-mode cannula: spring-loaded for self-insertion or manually operated as per user preference. Its precise design enables single-attempt vein access, eliminating side-to-side needle movement that causes pain, bruising, and infiltration.
📉 Cost Savings for Procurement and Insurance
1. Reduce Cannula Wastage by 33%:
Every failed attempt leads to a wasted cannula, more staff time, and increased patient distress. By reducing failed attempts, Venaican saves up to 1 in 3 cannulae, lowering procurement costs dramatically.
2. Cut Iatrogenic Costs:
Complications from multiple cannulation attempts, such as phlebitis, extravasation, and infections, not only increase patient stay but also result in non-reimbursed medical costs. Venaican can minimise these events, saving up to ₹15,000–₹1,50,000 ($200–$2,000) per patient in insurance losses.
3. Lower Drug and Hospital Stay Costs:
Every day reduced in hospital stay can save ₹ $6,000–₹ $12,000 ($80–$160). Venaican's precision avoids complications and accelerates treatment delivery, leading to faster patient discharge.
4. Eco-Friendly:
Cannulation generates hundreds of tons of medical plastic waste per hospital annually. Venaican's reduced failure rate cuts medical waste significantly, aligning with ESG (Environmental, Social, and Governance) goals.
⚙️ For Manufacturers and Distributors: A High-Demand, Low-Cost Opportunity
- Manufacturing cost per unit is lower than the existing cannula due to minimal additional materials.
- Can be made using existing cannula production lines with minor design adjustments.
- Offers dual-mode operation—a major USP for international tenders and emerging markets.
- Already tested, published, and designed with ergonomic and metric standards.
Market Potential:
- Global IV cannula market projected to exceed $100 billion by 2027.
- Public and private hospitals conduct millions of cannulations daily, with at least 15–20% failure.
- High demand from military, emergency, pediatric, and pandemic care units.
🏥 For Hospitals and Ministries of Health
- Improves nursing success rate in first attempts, reducing patient trauma.
- Reduces doctor workload and liability in high-risk infectious environments.
- It can be deployed rapidly during pandemics or emergencies without compromising healthcare worker safety.
- Perfect for rural, resource-limited areas where expertise and sterile conditions are scarce.
📢 Call to Action
If you are:
- A procurement officer seeking to reduce supply waste and cost per patient,
- A health ministry trying to prevent AMR and iatrogenic infections,
- A hospital administrator planning to improve efficiency and safety,
- Or a distributor/manufacturer looking to introduce a new product with massive global appeal,
Now is the time to bring Venaican to your institution and the world.
Join the global shift towards cost-effective, safe, and patient-friendly healthcare. Contact us to place a bulk order, license the technology, or co-brand and distribute Venaican in your region.
Contact for Orders, Manufacturing Partnerships, and Distribution Rights
Dr Kadiyali M Srivatsa
- 📧 medifix@gmial.com
- 🌐 Website: VENAICAN.COM
- 📞 Phone: +91 84311 33959
🏥 Available for demos, tenders, and government pilot programs.